Determinantes de la probabilidad de padecer enfermedades inflamatorias intestinales
Date
Authors
Subject
calprotectin
ulcerative colitis
Crohn’s disease
Probit
Logit models
JEL Codes
I10
I12
C25
calprotectina
colitis ulcerativa
enfermedad Crohn
Probit
Logit
Códigos JEL
I10
I12
C25
ulcerative colitis
Crohn’s disease
Probit
Logit models
JEL Codes
I10
I12
C25
calprotectina
colitis ulcerativa
enfermedad Crohn
Probit
Logit
Códigos JEL
I10
I12
C25
Language:
Journal Title
Journal ISSN
Volume Title
Publisher
Instituto Tecnológico de Santo Domingo (INTEC)
En base a un universo de 116 pacientes, realizamos un estudio observacional descriptivo transversal y de recolección de datos prospectivo con el fin de determinar la eficacia de la calprotectina fecal en pacientes conocidos y con alta sospecha de enfermedad inflamatoria del intestino. A diferencia de estudios anteriores, utilizamos una serie de modelos econométricos para estimar la probabilidad de que un paciente padezca Colitis Ulcerativa o Enfermedad del Crohn (CU-EC) dado el nivel de calprotectina detectado en las heces fecales. Los resultados indican que esta probabilidad puede diferir en magnitudes significativas dependiendo del sexo, la edad y los hábitos de consumo del paciente. Por ejemplo, en el caso de los hombres, la probabilidad de padecer CU-EC es significativamente mayor que para las mujeres, incluso en niveles bajos de calprotectina fecal. Además, la razón de probabilidades de padecer CU-EC aumenta hasta que el paciente alcanza los 37 años, edad en que la probabilidad de contraer una enfermedad inflamatoria intestinal comienza a reducirse paulatinamente. Finalmente, la probabilidad de que un paciente padezca CUEC es mayor para las personas que declaran ser fumadoras de tabaco, a pesar de que este último resultado no aparenta ser significativo en términos estadísticos.
Based on a universe of 116 patients, we conducted a cross-sectional and prospective data collection descriptive observational study to determine the effectiveness of fecal calprotectin in known and highly suspected inflammatory bowel disease patients. Unlike previous studies, we use a series of econometric to estimate the probability that a patient suffering from ulcerative colitis or Crohn's disease (CU-EC) given the level of calprotectin detected in the stool models. The results indicate that this probability may differ in significant quantities depending on sex, age and habits of the patient. For example, in the case of men, the likelihood of developing CU-EC is significantly higher than for women, even at low levels of fecal calprotectin. In addition, the odds ratio of developing CU-EC increased until the patient reaches age 37, age at which the chance of developing inflammatory bowel disease begins to gradually decline. Finally, the probability that a patient has UC-EC is higher for people who say they smoke to snuff, even though this result seems not be significant in statistical terms.
Based on a universe of 116 patients, we conducted a cross-sectional and prospective data collection descriptive observational study to determine the effectiveness of fecal calprotectin in known and highly suspected inflammatory bowel disease patients. Unlike previous studies, we use a series of econometric to estimate the probability that a patient suffering from ulcerative colitis or Crohn's disease (CU-EC) given the level of calprotectin detected in the stool models. The results indicate that this probability may differ in significant quantities depending on sex, age and habits of the patient. For example, in the case of men, the likelihood of developing CU-EC is significantly higher than for women, even at low levels of fecal calprotectin. In addition, the odds ratio of developing CU-EC increased until the patient reaches age 37, age at which the chance of developing inflammatory bowel disease begins to gradually decline. Finally, the probability that a patient has UC-EC is higher for people who say they smoke to snuff, even though this result seems not be significant in statistical terms.
Description
Type
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
info:eu-repo/semantics/publishedVersion
Source
Science, Economy & Business; Vol 1 No 1 (2017): Science, Economics and Business; 157-185
Ciencia, Economía y Negocios; Vol. 1 Núm. 1 (2017): Ciencia, Economía y Negocios; 157-185
2613-8778
2613-876X
10.22206/ceyn.2017.v1i1
Ciencia, Economía y Negocios; Vol. 1 Núm. 1 (2017): Ciencia, Economía y Negocios; 157-185
2613-8778
2613-876X
10.22206/ceyn.2017.v1i1